Guilin Sanjin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002275.SZ

Guilin Sanjin Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2023: 23.87%

Guilin Sanjin Pharmaceutical Co., Ltd. EBT Margin is 23.87% for the year ending December 31, 2023, a 4.83% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Guilin Sanjin Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2022 was 22.77%, a -7.60% change year over year.
Guilin Sanjin Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2021 was 24.64%, a 12.16% change year over year.
Guilin Sanjin Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2020 was 21.97%, a -22.93% change year over year.
Guilin Sanjin Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2019 was 28.51%, a -8.87% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Shenzhen Stock Exchange: 002275.SZ

Guilin Sanjin Pharmaceutical Co., Ltd.

CEO	Mr. Xun Zou
IPO Date	July 10, 2009
Location	China
Headquarters	No.1, Gold Star(Jinxing) Road
Employees	2,615
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods

Description

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand; and Naomaitai capsules, etc. It also produces TCM preparations. The company was founded in 1967 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.

Key trends

Past 5 years